Clinical Trials
23 trialsNCT02911571 2026-04-28
PROMMIS
SkylineDx
Phase NA Active not recruiting
NCT06068400 2026-03-17
Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma
Guangzhou Bio-gene Technology Co., Ltd
Phase NA Terminated
NCT05587972 2026-02-23
Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring
Carevive Systems, Inc.
Phase NA Active not recruiting
NCT07100067 2025-12-29
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
Nanjing Legend Biotech Co.
Phase NA Recruiting
NCT07248176 2025-12-01
Universal CAR-T Cell Therapy for MM
Bioray Laboratories
Phase NA Recruiting
NCT07195617 2025-09-26
r/r MM
Guangzhou Bio-gene Technology Co., Ltd
Phase NA Not yet recruiting
NCT05618041 2025-06-24
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Recruiting
NCT05956457 2025-04-20
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
Pack Health
Phase NA Recruiting
NCT05053607 2024-12-11
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
Pack Health
Phase NA Recruiting
NCT05260203 2024-11-06
MargheRITA
Advice Pharma Group srl
Phase NA Completed
NCT05064787 2024-05-24
Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy
Pack Health
Phase NA Completed
NCT06279026 2024-02-26
UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase NA Recruiting
NCT05308875 2024-01-05
Efficacy and Safety Evaluation of PD1-BCMA-CART
Bioray Laboratories
Phase NA Unknown
NCT05619861 2022-11-17
CAR-T Cells in the Treatment of Malignant Hematological Tumors
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Unknown
NCT03752541 2022-05-20
Efficacy and Safety Evaluation of BCMA-UCART
Bioray Laboratories
Phase NA Suspended
NCT03492268 2022-05-17
Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma
Bioray Laboratories
Phase NA Withdrawn
NCT04447573 2020-09-29
Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Unknown
NCT00656305 2020-02-05
ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
InSightec
Phase NA Completed
NCT03046329 2019-11-07
Improving the Quality of Multiple Myeloma Treatment With Patient Care Plans
Carevive Systems, Inc.
Phase NA Completed
NCT03068637 2018-06-15
Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma
Carevive Systems, Inc.
Phase NA Completed
NCT01423760 2016-10-06
Common Safety Follow-up Trial of Tecemotide (L-BLP25)
Merck KGaA, Darmstadt, Germany
Phase NA Terminated
NCT01292486 2013-05-01
Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure
Terumo BCT
Phase NA Completed
NCT01572688 2012-08-02
MM
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase NA Unknown